World Health Organization, 1999. Report of the WHO Informal Consultation on Schistosomiasis Control. WHO/CDS/CPC/ SIP/99.2. Geneva: World Health Organization.
World Health Organization, 2002. Prevention and Control of Schistosomiasis and Soil-Transmitted Helminthiasis: First Report of the Joint WHO Expert Committees. WHO Tech Rep Ser No. Geneva: World Health Organization. (in press)
Bergquist NR, 2002. Schistosomiasis: from risk assessment to control. Trends Parasitol 18 :309–314.
Chitsulo L, Engels D, Montresor A, Savioli L, 2000. The global status of schistosomiasis and its control. Acta Trop 77 :41–51.
Engels D, Chitsulo L, Montresor A, Savioli L, 2002. The global epidemiological situation of schistosomiasis and new approaches to control and research. Acta Trop 82 :139–146.
Cioli D, 2000. Praziquantel: is there real resistance and are there alternatives? Curr Opin Inf Dis 13 :659–663.
Gryseels B, Mbaye A, De Vlas SJ, Stelma FF, Guissé F, Van Lieshout L, Faye D, Diop M, Ly A, Tchuem-Tchuenté LA, Engels D, Polman K, 2001. Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop Med Int Health 6 :864–873.
Danso-Appiah A, De Vlas SJ, 2002. Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal. Trends Parasitol 18 :125–129.
Feldmeier H, Chitsulo L, 1999. Therapeutic and operational profiles of metrifonate and praziquantel in Schistosoma haematobium infection. Arzneimittelforschung 49 :557–565.
Beck L, Favre TC, Pieri OS, Zani LC, Domas GG, Barbosa CS, 2001. Replacing oxamniquine by praziquantel against Schistosoma mansoni infection in a rural community from the sugar-cane zone of northeast Brazil: an epidemiological follow-up. Mem Inst Oswaldo Cruz 96 (Suppl.) :165–167.
Reich MR, Fenwick A, 2001. Schistosoma haematobium. N Engl J Med 344 :1170.
Cioli D, 1998. Chemotherapy of schistosomiasis: an update. Parasitol Today 14 :418–422.
Gönnert R, Andrews P, 1977. Praziquantel, a new broad-spectrum antischistosomal agent. Z Parasitenkd 52 :129–150.
Sabah AA, Fletcher C, Webbe G, Doenhoff MJ, 1986. Schistosoma mansoni: chemotherapy of infections of different ages. Exp Parasitol 61 :294–303.
Price RN, 2000. Artemisinin drugs: novel antimalarial agents. Expert Opin Investig Drugs 9 :1815–1827.
Xiao SH, You JQ, Yang YQ, Wang CZ, 1995. Experimental studies on early treatment of schistosomal infection with artemether. Southeast Asian J Trop Med Public Health 26 :306–318.
Xiao SH, Chollet J, Weiss NA, Bergquist RN, Tanner M, 2000. Preventive effect of artemether in experimental animals infected with Schistosoma mansoni. Parasitol Int 49 :19–24.
Xiao SH, Utzinger J, Chollet J, Endriss Y, N’Goran EK, Tanner M, 2000. Effect of artemether against Schistosoma haematobium in experimentally infected hamsters. Int J Parasitol 30: 1001–1006.
Utzinger J, Xiao SH, N’Goran EK, Bergquist R, Tanner M, 2001. The potential of artemether for the control of schistosomiasis. Int J Parasitol 31: 1549–1562.
Xiao SH, Booth M, Tanner M, 2000. The prophylactic effects of artemether against Schistosoma japonicum infections. Parasitol Today 16 :122–126.
Utzinger J, N’Goran EK, N’Dri A, Lengeler C, Xiao SH, Tanner M, 2000. Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial. Lancet 355: 1320–1325.
Xiao SH, Chollet J, Utzinger J, Matile H, Mei JY, Tanner M, 2001. Artemether administered together with haemin damages schistosomes in vitro. Trans R Soc Trop Med Hyg 95 :67–71.
Xiao SH, Shen BG, Chollet J, Utzinger J, Tanner M, 2001. Tegumental alterations in juvenile Schistosoma haematobium harboured in hamsters following artemether treatment. Parasitol Int 50 :175–183.
Yang YQ, Xiao SH, Tanner M, Utzinger J, Chollet J, Wu JD, Guo J, 2001. Histopathological changes in juvenile Schistosoma haematobium harboured in hamsters treated with artemether. Acta Trop 79 :135–141.
N’Goran EK, Utzinger J, N’Guessan AN, Müller I, Zamblé K, Lohourignon KL, Traoré M, Sosthène BA, Lengeler C, Tanner M, 2001. Reinfection with Schistosoma haematobium following school-based chemotherapy with praziquantel in four highly endemic villages in Côte d’Ivoire. Trop Med Int Health 6: 817–825.
Plouvier S, Leroy J-C, Colette J, 1975. A propos d’une technique simple de filtration des urines dans le diagnostic de la bilhar-ziose urinaire en enquête de masse. Med Trop 35 :229–230.
Hatz CFR, 2001. The use of ultrasound in schistosomiasis. Adv Parasitol 48 :225–284.
N’Goran EK, Diabate S, Utzinger J, Sellin B, 1997. Changes in human schistosomiasis levels after the construction of two large hydroelectric dams in central Côte d’Ivoire. Bull World Health Organ 75: 541–545.
Utzinger J, Xiao SH, Keiser J, Chen MG, Zheng J, Tanner M, 2001. Current progress in the development and use of artemether for chemoprophylaxis of major human schistosome parasites. Curr Med Chem 8 :1841–1860.
Li S, Wu L, Liu Z, Hu L, Xu P, Xuan Y, Liu Y, Liu X, Fan J, 1996. Studies on prophylactic effect of artesunate on schistosomiasis japonica. Chin Med J 109 :848–853.
Utzinger J, Chollet J, Tu ZW, Xiao SH, Tanner M, 2002. Comparative study of the effects of artemether and artesunate on juvenile and adult Schistosoma mansoni in experimentally infected mice. Trans R Soc Trop Med Hyg 96 :318–323.
Borrmann S, Szlezák N, Faucher J-F, Matsiegui P-B, Neubauer R, Binder RK, Lell B, Kremsner PG, 2001. Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: a double-blind, randomized, placebo-controlled study. J Infect Dis 184 :1363–1366.
De Clercq D, Vercruysse J, Kongs A, Verlé P, Dompnier JP, Faye PC, 2002. Efficacy of artesunate and praziquantel in Schistosoma haematobium-infected schoolchildren. Acta Trop 82 :61–66.
Ghandour AM, 1978. The development of Schistosoma haematobium in the hamster. Ann Trop Med Parasitol 72 :219–225.
Xiao SH, You JQ, Mei JY, Guo HF, Jiao PY, Tanner M, 2000. Effect of praziquantel together with artemether on Schistosoma japonicum parasites of different ages in rabbits. Parasitol Int 49 :25–30.
Utzinger J, Chollet J, You JQ, Mei JY, Tanner M, Xiao SH, 2001. Effect of combined treatment with praziquantel and artemether on Schistosoma japonicum and Schistosoma mansoni in experimentally infected animals. Acta Trop 80 :9–18.
De Clercq D, Vercruysse J, Verlé P, Kongs A, Diop M, 2000. What is the effect of combining artesunate and praziquantel in the treatment of Schistosoma mansoni infections? Trop Med Int Health 5 :744–746.
White N, 1999. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci 354 :739–749.
Xiao SH, Tanner M, N’Goran EK, Utzinger J, Chollet J, Bergquist R, Chen MG, Zeng J, 2002. Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia. Acta Trop 82: 175–181.
Haynes RK, 2001. Artemisinin and derivatives: the future for malaria treatment? Curr Opin Infect Dis 14 :719–726.
World Health Organization, 2001. Potential Use of Artemisinins for Prevention of Schistosomiasis. Report of a Meeting Held in Geneva, Switzerland, from January 29–30, 2001. Geneva: World Health Organization.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||351||204||2|
Artemether is an efficacious antimalarial drug that also displays antischistosomal properties. Laboratory studies have found that artemether curtails the development of adult worms of Schistosoma japonicum, S. mansoni, and S. haematobium, and thus prevents morbidity. These findings have been confirmed in clinical trials for the former two parasites; administered orally once every 2–3 weeks, artemether significantly reduced the incidence and intensity of patent infections. Here, we present the first randomized, double-blind, placebo-controlled trial of artemether against S. haematobium, done in a highly endemic area of Côte d’Ivoire. Urine specimens from 440 schoolchildren were examined over 4 consecutive days, followed by two systematic praziquantel treatments 4 weeks apart. S. haematobium-negative children were randomized to receive 6 mg/kg artemether (N = 161) or placebo (N = 161). Medication was administered orally for a total of six doses once every 4 weeks. Adverse events were assessed 72 hours after medication, and perceived illness episodes were monitored throughout the study period. Incidence and intensity of S. haematobium infections, and microhematuria and macrohematuria were assessed 3 weeks after the final dosing. We also monitored malaria parasitemia and treated positive cases with sulfadoxine-pyrimethamine (SP). Oral artemether was well tolerated. The incidence of patent S. haematobium infections in artemether recipients was significantly lower than in placebo recipients (49% versus 65%, protective efficacy: 0.25, 95% CI: 0.08–0.38, P = 0.007). The geometric mean infection intensity in the artemether group was less than half that of the placebo recipients (3.4 versus 7.4 eggs/10 mL urine, P < 0.001). Heavy S. haematobium infections, microhematuria and macrohematuria, and the incidence of malaria parasitemia were all significantly lower in artemether recipients. In conclusion, previous findings of efficacy of artemether against S. japonicum and S. mansoni were confirmed for S. haematobium, although the protective efficacy was considerably lower. These findings enlarge the scope and potential of artemether and further contribute to discussions of its role as an additional tool for integrated schistosomiasis control.